|
Aug 13
|
IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions
|
|
Aug 12
|
IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode
|
|
Jun 24
|
Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference
|
|
Jun 21
|
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
|
|
Jun 12
|
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
|
|
Jun 11
|
Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now
|
|
May 28
|
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
|
|
May 14
|
Clene to Present at Upcoming May Conferences
|
|
May 9
|
Clene First Quarter 2024 Earnings: Misses Expectations
|
|
May 8
|
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
|
|
May 1
|
IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington
|
|
Apr 23
|
Bullish Clene Insiders Loaded Up On US$9.58m Of Stock
|
|
Apr 16
|
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
|
|
Mar 19
|
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
|
|
Mar 15
|
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
|
|
Mar 13
|
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
|
|
Mar 7
|
Clene to Present at the 36th Annual ROTH Conference
|
|
Feb 5
|
Clene Inc. announces positive results from CNM-Au8 results from MS trial
|
|
Jan 24
|
Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment
|
|
Jan 10
|
Clene Announces Significant Positive Results from LTE VISIONARY-MS Trial
|